Target Price | JPY5,528.40 |
Price | JPY5,333.00 |
Potential |
3.66%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Kobayashi Pharmaceutical 2026 .
The average Kobayashi Pharmaceutical target price is JPY5,528.40.
This is
3.66%
register free of charge
JPY7,035.00
31.91%
register free of charge
JPY5,050.00
5.31%
register free of charge
|
|
A rating was issued by 12 analysts: 5 Analysts recommend Kobayashi Pharmaceutical to buy, 7 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Kobayashi Pharmaceutical stock has an average upside potential 2026 of
3.66%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion JPY | 165.60 | 172.17 |
4.53% | 3.97% | |
EBITDA Margin | 17.93% | 15.18% |
7.33% | 15.36% | |
Net Margin | 6.08% | 7.82% |
48.15% | 28.64% |
9 Analysts have issued a sales forecast Kobayashi Pharmaceutical 2025 . The average Kobayashi Pharmaceutical sales estimate is
This results in the following potential growth metrics:
9 Kobayashi Pharmaceutical Analysts have issued a net profit forecast 2025. The average Kobayashi Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share JPY | 135.42 | 181.21 |
49.50% | 33.81% | |
P/E | 29.33 | |
EV/Sales | 1.90 |
9 Analysts have issued a Kobayashi Pharmaceutical forecast for earnings per share. The average Kobayashi Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Kobayashi Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.